ArticleClinical case reports2025
Retrogasserian Glycerol Rhizotomy (RGGR) for Trigeminal Neuralgia Induced by Postvaccination Herpetic Reactivation: A Rare Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retrogasserian Glycerol Rhizotomy (RGGR) for Trigeminal Neuralgia Induced by Postvaccination Herpetic Reactivation: A Rare Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports on surgical treatment for postherpetic trigeminal neuralgia after COVID vaccination have not been found in the literature. Here, we described a case of postherpetic trigeminal neuralgia after COVID vaccination that was treated with percutaneous retrogasserian glycerol rhizotomy (PRGR) resulting in complete pain relief. We reported a case involving a 70-year-old female who had herpes zoster infection in the ophthalmic branch (V1) dermatome following COVID vaccination and presented with paroxysmal electric shock-like sensation without a trigger. Her pain was refractory to medical management. Her Barrow Neurological Institute pain intensity score was IV. Magnetic resonance imaging of the brain was normal. PRGR was performed. The patient's pain decreased over the next 2 h, and she was pain-free from post-procedure Day 2 while taking carbamazepine 400 mg/day, which was tapered over 2 weeks. At her 3-month follow-up, the patient was reviewed and remained pain-free. Percutaneous treatment of postherpetic trigeminal neuralgia may be considered the treatment of choice in vaccination-induced postherpetic trigeminal neuralgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.